FCF Biotech
Venture Capital Monitor
-
USA

The FCF Biotech Venture Capital Monitor – USA is a monthly published overview of venture capital trends in the US-Biotech sector.

FCF Biotech Venture Capital Monitor - USA

As of the end of December 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 23,607m
  • Compared to December 2022 the financing volume decreased by roughly 26% (31,894m vs. 23,607m)
  • The top 5 deals exceed USD 273m each, the largest transaction amounted to USD 401m with ElevateBio
  • Bicara Therapeutics has the highest transaction Volume of USD 165m in December, followed by Lyndra Therapeutics USD 123m and Tome Biosciences USD 118m
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and OrbiMed (USA)
  • As an indication oncology records the highest investment activity

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS